Is Zoetis Inc (ZTS) overvalued? · P/E 25, rev $9.47B
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Zoetis Inc (ZTS) looks expensive on cached numbers — not a short thesis.
Latest reported ZTS revenue for 2025-12-31 was $9.47B. Net income was $2.67B. Revenue was up 2.3% from 2024-12-31 to 2025-12-31. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
ZTS currently screens at market cap $64.65B and trailing P/E 24.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ZTS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ZTS stock page for the full model, not this heading.
Not investment advice.